Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Mirtazapine

FDA-approved product (tablet, oral), marketed as Mirtazapine, Remeron, Remeron Soltab.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Mirtazapine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Depressive disorder
  • Insomnia
  • Major depressive disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antidepressants
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA38.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli38.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae25.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Mirtazapine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Mirtazapine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Adjunctive Mixed Salts Amphetamine for Depressed Adults With Incomplete Response to Current Antidepressant Therapy

    NCT02058693 · start 2010-12

    Registered record
    Registry ID
    NCT02058693
    Conditions
    Major Depressive Disorder
    Interventions
    mixed salts amphetamine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-12
    Completion
    2014-12
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    Interventionmixed salts amphetamine
    PhasePhase 4
    Registry statusCompleted

  • A Study of Quetiapine and Mirtazapine for the Treatment of Alcohol Dependency

    NCT01165541 · start 2010-09

    Registered record
    Registry ID
    NCT01165541
    Conditions
    Alcohol Dependence
    Interventions
    Mirtazapine; Quetiapine fumarate extended release (Quetiapine XR)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-09
    Completion
    2012-10
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlcohol Dependence
    InterventionMirtazapine; Quetiapine fumarate extended release (Quetiapine XR)
    PhasePhase 2
    Registry statusCompleted

  • Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders

    NCT01302964 · start 2010-08

    Registered record
    Registry ID
    NCT01302964
    Conditions
    Autism Spectrum Disorders
    Interventions
    Placebo; Mirtazapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-08
    Completion
    2017-10-10
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAutism Spectrum Disorders
    InterventionPlacebo; Mirtazapine
    PhasePhase 3
    Registry statusCompleted

  • Combined Mirtazapine and SSRI Treatment of PTSD: A Placebo-Controlled Trial

    NCT01178671 · start 2010-07

    Registered record
    Registry ID
    NCT01178671
    Conditions
    Posttraumatic Stress Disorder
    Interventions
    Mirtazapine; Sertraline; Sugar pill
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-07
    Completion
    2014-06
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPosttraumatic Stress Disorder
    InterventionMirtazapine; Sertraline; Sugar pill
    PhasePhase 4
    Registry statusCompleted

  • A Clinical Study for Assessment of the Efficacy and Safety of Mirtazapine (Smilon) in Depression Patients With Pain

    NCT01119924 · start 2009-12

    Registered record
    Registry ID
    NCT01119924
    Conditions
    Depression; Pain
    Interventions
    Smilon®; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-12
    Completion
    2010-11
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression; Pain
    InterventionSmilon®; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Study of Indoleamine 2,3-dioxygenase Activity, Serum Levels of Cytokines, BDNF, BH4 and Mirtazapine Efficacy in Fibromyalgia Syndrome

    NCT00919295 · start 2008-12

    Registered record
    Registry ID
    NCT00919295
    Conditions
    Fibromyalgia Syndrome
    Interventions
    mirtazapine; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-12
    Completion
    2011-12
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFibromyalgia Syndrome
    Interventionmirtazapine; placebo
    PhasePhase 2
    Registry statusCompleted

  • Twenty-six Week Extension Trial of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia (176003/P05721/MK-8265-007)

    NCT00750919 · start 2008-10-07

    Registered record
    Registry ID
    NCT00750919
    Conditions
    Sleep Initiation and Maintenance Disorders; Mental Disorders; Dyssomnias; Sleep Disorders; Sleep Disorders, Intrinsic
    Interventions
    esmirtazapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2008-10-07
    Completion
    2010-03-10
    Enrolment
    184

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSleep Initiation and Maintenance Disorders; Mental Disorders; Dyssomnias; Sleep Disorders +1 more
    Interventionesmirtazapine
    PhasePhase 3
    Registry statusTerminated

  • A 6-Month Efficacy and Safety Study of Org 50081 in Adult Patients With Chronic Primary Insomnia (21106/P05701/MK-8265-002)

    NCT00631657 · start 2008-03-04

    Registered record
    Registry ID
    NCT00631657
    Conditions
    Sleep Initiation and Maintenance Disorders; Mental Disorders; Dyssomnias; Sleep Disorders; Sleep Disorder, Intrinsic
    Interventions
    Esmirtazapine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-03-04
    Completion
    2009-11-19
    Enrolment
    460

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSleep Initiation and Maintenance Disorders; Mental Disorders; Dyssomnias; Sleep Disorders +1 more
    InterventionEsmirtazapine; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Long-Term Safety Study of Org 50081 (Esmirtazapine) in Elderly Outpatients With Chronic Primary Insomnia (176005/P05697/MK-8265-001)

    NCT00561574 · start 2008-01-09

    Registered record
    Registry ID
    NCT00561574
    Conditions
    Sleep Initiation and Maintenance Disorder; Elderly; Mental Disorder; Dyssomnias; Sleep Disorders; Sleep Disorder, Intrinsic
    Interventions
    Esmirtazapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-01-09
    Completion
    2010-02-14
    Enrolment
    259

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSleep Initiation and Maintenance Disorder; Elderly; Mental Disorder; Dyssomnias +2 more
    InterventionEsmirtazapine
    PhasePhase 3
    Registry statusCompleted

  • Dose Response of Mirtazapine to Methamphetamine Induced Interest, Mood Elevation and Reward

    NCT00600145 · start 2007-09

    Registered record
    Registry ID
    NCT00600145
    Conditions
    Amphetamine Dependence
    Interventions
    Mirtazapine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2007-09
    Completion
    2010-07
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAmphetamine Dependence
    InterventionMirtazapine; Placebo
    PhaseNot applicable
    Registry statusWithdrawn

  • Treatment of Mood and Marriage Study (TOMMS)

    NCT00612807 · start 2006-07

    Registered record
    Registry ID
    NCT00612807
    Conditions
    Major Depressive Disorder; Partner Relational Disorder (V61.10)
    Interventions
    Weekly marital therapy; As indicated: Sertraline, bupropion, venlafaxine, mirtazepine, nortriptyline, tranylcypromine, lithium augmentation, etc.
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2006-07
    Completion
    2010-06
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder; Partner Relational Disorder (V61.10)
    InterventionWeekly marital therapy; As indicated: Sertraline, bupropion, venlafaxine, mirtazepine, nortriptyline, tranylcypromine, lithium augmentation, etc.
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy

    NCT00150839 · start 2006-03

    Registered record
    Registry ID
    NCT00150839
    Conditions
    Depressive Disorder, Major
    Interventions
    Mirtazapine; Venlafaxine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-03
    Completion
    2009-12
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepressive Disorder, Major
    InterventionMirtazapine; Venlafaxine
    PhasePhase 4
    Registry statusCompleted

  • PET Neuroimaging of [11C]Mirtazapine

    NCT00288782 · start 2006-02

    Registered record
    Registry ID
    NCT00288782
    Conditions
    Mental Disorders; Mood Disorders; Affective Disorders; Depressive Disorders
    Interventions
    Mirtazapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-02
    Completion
    2007-04
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMental Disorders; Mood Disorders; Affective Disorders; Depressive Disorders
    InterventionMirtazapine
    PhasePhase 4
    Registry statusCompleted

  • Efficacy of Mirtazapine in Depressed Cocaine Dependent Subjects

    NCT00322309 · start 2005-09

    Registered record
    Registry ID
    NCT00322309
    Conditions
    Cocaine Dependence; Depression
    Interventions
    Placebo; Mirtazapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-09
    Completion
    2010-02
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCocaine Dependence; Depression
    InterventionPlacebo; Mirtazapine
    PhasePhase 2
    Registry statusCompleted

  • The Effects of Mirtazapine Versus Placebo on Alcohol Consumption in Male Alcohol High Consumers

    NCT00874003 · start 2004-04

    Registered record
    Registry ID
    NCT00874003
    Conditions
    Alcohol Dependence
    Interventions
    mirtazapine; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-04
    Completion
    2009-02
    Enrolment
    59

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlcohol Dependence
    Interventionmirtazapine; placebo
    PhasePhase 2
    Registry statusCompleted